Ranbaxy Laboratories lost 2.43% to Rs 445.40 at 13:56 IST on BSE after consolidated net profit declined 89.91% to Rs 125.75 crore on 33.29% decline in total income to Rs 2562.96 crore in Q1 March 2013 over Q1 March 2012.
The company announced Q1 results during trading hours today, 8 May 2013.
Meanwhile, the S&P BSE Sensex was up 58.61 points or 0.29% at 19,947.56.
On BSE, 2.49 lakh shares were traded in the counter as against average daily volume of 1.13 lakh shares in the past one quarter.
The stock hit a high of Rs 460 and a low of Rs 442.35 so far during the day. The stock had hit a 52-week low of Rs 370.50 on 1 March 2013. The stock had hit a 52-week high of Rs 578.30 on 4 September 2012.
The stock had underperformed the market over the past one month till 7 May 2013, rising 1.56% compared with the Sensex's 7.8% surge. The scrip had, however, outperformed the market in past one quarter, surging 4.75% as against Sensex's 1.58% rise.
Also Read
The large-cap pharmaceutical company has equity capital of Rs 211.55 crore. Face value per share is Rs 5.
Ranbaxy Laboratories is an integrated, research based, international pharmaceutical company producing a wide range of generic medicines. Ranbaxy serves its customers in over 150 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 43 countries and manufacturing operations in 8 countries. Ranbaxy is a member of the Daiichi Sankyo Group.
Powered by Capital Market - Live News